ArticleAnnals of nuclear medicine2026
Visceral technetium-99 m-labeled pyrophosphate uptake in patients with wild-type transthyretin cardiac amyloidosis.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTechnetium-99 m-labeled pyrophosphate (Tc-99 m-PYP) scintigraphy can image tracer uptake in the myocardium, subcutaneous fat, and skeletal muscles of patients with wild-type amyloid transthyretin (ATTRwt) cardiac amyloidosis (CA), which indicates ATTR deposition. However, there are few reports of visceral Tc-99 m-PYP uptake in patients with ATTRwt-CA. This study was conducted to determine whether Tc-99 m-PYP scintigraphy can image ATTR deposition in the viscera, particularly the liver, spleen, and gastrointestinal tract.
methodsChest- and abdomen-centered Tc-99 m-PYP scintigraphy with single-photon emission computed tomography-computed tomography fusion images were acquired 2 h after patients with clinically suspected CA were intravenously injected with 20 mCi of the tracer. The participants were divided into two groups: ATTR-CA and non-ATTR-CA groups. Semi-quantitative visual grade of hepatic tracer uptake and mean standardized uptake values in the liver (SUVmean-L) were investigated. The presence or absence of tracer uptake in the spleen and alimentary tract (stomach, small intestine, and colon, excluding the rectum and anus) was also investigated.
resultsOf 209 participants (median age, 85 years; range, 79–90 years; 56.5% male), 72 patients, all of whom had ATTRwt-CA, were assigned to the ATTR-CA group, whereas 137 were assigned to the non-ATTR-CA group. Semi-quantitative visual grade of hepatic tracer uptake, SUVmean-L, and the rate of splenic tracer uptake did not vary between both groups (p = 0.100, p = 0.904, and p = 0.356, respectively). However, the ATTR-CA group showed a higher rate of tracer uptake in the alimentary tract than the non-ATTR-CA group (p < 0.001). Within the digestive tract, the tracer uptake rates in the small intestine and colon were significantly higher in the ATTR-CA group than in the non-ATTR-CA group (p < 0.001 and p < 0.001, respectively); however, no significant difference was observed in gastric accumulation between the two groups (p = 0.305).
conclusionsTc-99 m-PYP scintigraphy may image ATTR deposition in the small intestine and colon of patients with ATTRwt-CA. In contrast, Tc-99 m-PYP uptake likely reflects blood pool activity rather than ATTR deposition in the liver, spleen, and stomach.
Indexed as
Identifiers
41989649What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.